

**Media release 04 January 2017**

### **CE marking awarded to Parkinson's digital health technology**

Global Kinetics Corporation, leader in digital health technology for people with Parkinson's has secured CE marking on its new second generation *Parkinson's KinetiGraph™ (PKG™) system*, indicating that the product complies with European health and safety requirements and legislation.

The Parkinson's KinetiGraph™ (PKG™) system is a patient-friendly, algorithm-based system that records body movements and other symptoms over the course of seven days and creates data-driven reports that empower more personalised treatment and management decisions—with the goal of leading to a higher quality of life for patients.

The first generation PKG™ system is already used in a number of countries throughout Europe including Sweden, Finland, Germany, France, Netherlands and the UK.

The CE marking of the second generation technology signals a major milestone for Global Kinetics Corporation. The new technology has also recently received clearance from the US Food and Drug Administration (FDA) and has been trialled in Australia, where it received avid support from patients.

The second generation system boasts technological enhancements which could ultimately allow patients themselves (in addition to their clinician) to monitor their condition 24 hours a day, 365 days a year (or “anytime, anywhere”) in order to better manage and control their symptoms.

Clinicians receive detailed reports of the patient's movements, helping to assess the impact of the disease on the patient's everyday life and amend their therapy regime accordingly – enabling personalised care.

New patient friendly features of the second generation PKG™ system include a more modern and discrete design for the wrist worn device, known as the PKG™ watch. The new PKG™ watch is similar to a smart watch and includes a vibrating alarm and LED light for medication reminders. It is also now water resistant so that it may be worn continuously.

CEO and President of Global Kinetics Corporation, Timothy I Still, said the CE marking of the new technology underpins the company's aggressive expansion into new product and service offerings to meet the needs of the Parkinson's community worldwide.

“Global Kinetics continues to deliver on its strategic business objectives while remaining steadfast in our mission to make a meaningful difference for people with Parkinson's. We recently celebrated delivery of our 13,000th *PKG™* report – and look forward to a new era of impact for patients around the world with our second generation *PKG™* system.

“The second generation *PKG™* platform enables us to capitalise on our growing telehealth and clinical trial services businesses, and to build upon our already substantial partnerships with global pharmaceutical and device leaders in the area of Parkinson's.”

The *PKG™* system is already having a significant impact for people with Parkinson's in the UK. Dr Camille Carroll, Regional Lead Peninsula Parkinson's Excellence Network, recently incorporated use of the *PKG™* system into the newly diagnosed patient pathway in



Plymouth. Dr Carroll says (the PKG™ system) undoubtedly enhances patient care, helping to titrate and optimise treatment regimes earlier and more effectively.

“In (Plymouth’s) complex patients, the PKG™ system helps in the identification of motor complications, and assists us in our clinical decision making, particularly with regard to adjunctive and non-oral therapies. “I am sure that patient care has improved as a result of our use of this (PKG™) technology,” Dr Carroll said.

Steve Ford, CEO of Parkinson’s UK, has partnered with Global Kinetics since 2014 to enable access to the first generation PKG™ system for people in the UK living with Parkinson’s.

“The second generation PKG™ system is an exciting development which potentially provides a powerful platform enabling people with Parkinson’s to take control of their Parkinson’s,” Mr Ford said.

The new technology will be introduced to patients and clinicians in twelve leading European movement disorder clinics in the next two months, with a full rollout to follow thereafter.

**ENDS**

For more information, images or interview requests please contact Victoria Mayman or Kathryn Ager [Victoria.mayman@grayling.com](mailto:Victoria.mayman@grayling.com) / 0044 (0)20 3861 3827 [kathryn.ager@grayling.com](mailto:kathryn.ager@grayling.com) / 0044 (0)203 861 3887

**Follow updates from Global Kinetics Corporation via the company LinkedIn page.**

<https://www.linkedin.com/company/globalkineticscorp>

#### **About Global Kinetics Corporation**

Global Kinetics is a commercial-stage digital health company revolutionising the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments. The company’s Parkinson’s KinetiGraph (PKG) is a patient-friendly, algorithm-based system that records body movements and other symptoms over the course of many days and creates data-driven reports that empower more personalized treatment and management decisions—with the goal of leading to a higher quality of life for patients. Global Kinetics continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure the efficacy of new and advanced therapies for the world’s most widespread movement disorder.

For more information, visit: [www.globalkineticscorporation.com](http://www.globalkineticscorporation.com)